Antibacterial Resistance Leadership Group (ARLG)

A Multicenter, Three-Stage Cluster-Randomized Historically Controlled Crossover Trial to Determine the Feasibility and Outcomes from Two Antimicrobial Stewardship Interventions in Community Hospitals

Funding Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)

Funding Mechanism: 1UM1AI104681-01

Protocol Date: May 07, 2014
Protocol Version: 1.0
Principal Investigator: Deverick Anderson, MD, MPH
Professor of Medicine – Infectious Diseases
Duke University Medical Center
Duke Box 102359
Hanes House, Room 165
Durham, NC 27710
Telephone: 919-684-4596
Fax: 919-681-7494
E-mail: deverick.anderson@duke.edu
STATEMENT OF COMPLIANCE

This study will be conducted in compliance with the applicable principles and regulatory requirements from the United States Code of Federal Regulations (CFR), including 21 CFR 56 (institutional review board [IRB]) and 21 CFR 50 (informed consent) and to the principles outlined in applicable ICH guidelines.

STUDY PRINCIPAL INVESTIGATOR SIGNATURE

The signature below documents the review and approval of this protocol and provides the necessary assurances that this study will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and to the principles outlined in applicable U.S. federal regulations and ICH guidelines.

Deverick Anderson, MD, MPH

ARLG Study Principal Investigator

__________________________________________

Signature

__________________________________________

Date
# TABLE OF CONTENTS

Statement of Compliance and Signature Page ................................................................................ i
Table of Contents ................................................................................................................................. ii
List of Abbreviations .............................................................................................................................. iv
Protocol Synopsis ................................................................................................................................. v
Schematic/Description of Study Design ............................................................................................... vi

1  Key Roles ........................................................................................................................................ 8
2  Background Information and Scientific Rationale ................................................................. 9
   2.1 Background Information ............................................................................................... 9
   2.2 Scientific Rationale ....................................................................................................... 9
   2.3 Potential Risks and Benefits ......................................................................................... 9
       2.3.1 Potential Risks ............................................................................................... 9
       2.3.2 Benefits .......................................................................................................... 9
3  Objectives ....................................................................................................................................... 10
   3.1 Study Hypotheses and Objectives ............................................................................... 10
       3.1.1 Hypotheses .................................................................................................. 10
       3.1.2 Primary Objectives ....................................................................................... 10
       3.1.3 Secondary Objectives .................................................................................. 11
       3.1.4 Exploratory Objective ................................................................................... 11
4  Study Design ................................................................................................................................... 12
   4.1 Study Population ............................................................................................................ 12
       4.1.1 Selection of the Study Population .................................................................. 12
       4.1.2 Inclusion/Exclusion Criteria ......................................................................... 12
       4.1.3 Treatment Assignment Procedures .................................................................. 13
       4.1.4 Stewardship Strategy Descriptions ............................................................. 13
       4.1.5 Termination of Study .................................................................................... 14
5  Study procedures ............................................................................................................................. 15
   5.1 Data Collection .............................................................................................................. 15
   5.2 Other Study Procedures ............................................................................................... 16
6  Study Product Description ............................................................................................................. 17
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1</td>
<td>Concomitant Medications/Treatments</td>
<td>17</td>
</tr>
<tr>
<td>7</td>
<td>Assessment of Safety</td>
<td>18</td>
</tr>
<tr>
<td>8</td>
<td>Clinical Monitoring</td>
<td>19</td>
</tr>
<tr>
<td>9</td>
<td>Statistical Considerations</td>
<td>20</td>
</tr>
<tr>
<td>9.1</td>
<td>Design and Sample Size Considerations</td>
<td>20</td>
</tr>
<tr>
<td>9.2</td>
<td>Planned Interim Analyses</td>
<td>21</td>
</tr>
<tr>
<td>9.3</td>
<td>Participant Enrollment and Follow-Up</td>
<td>21</td>
</tr>
<tr>
<td>9.4</td>
<td>Analysis Plan</td>
<td>22</td>
</tr>
<tr>
<td>9.4.1</td>
<td>Analysis</td>
<td>22</td>
</tr>
<tr>
<td>9.4.2</td>
<td>Data Acquisition</td>
<td>24</td>
</tr>
<tr>
<td>9.4.3</td>
<td>Limitations and Potential Solutions</td>
<td>25</td>
</tr>
<tr>
<td>10</td>
<td>Study Implications</td>
<td>26</td>
</tr>
<tr>
<td>11</td>
<td>Participant Confidentiality</td>
<td>27</td>
</tr>
<tr>
<td>12</td>
<td>Informed Consent Process</td>
<td>28</td>
</tr>
<tr>
<td>13</td>
<td>Source Documents and Access to Source Data/Documents</td>
<td>29</td>
</tr>
<tr>
<td>14</td>
<td>Quality Control and Quality Assurance</td>
<td>30</td>
</tr>
<tr>
<td>15</td>
<td>Ethics/Protection of Human Participants</td>
<td>31</td>
</tr>
<tr>
<td>15.1</td>
<td>Institutional Review Board</td>
<td>31</td>
</tr>
<tr>
<td>15.2</td>
<td>Informed Consent</td>
<td>31</td>
</tr>
<tr>
<td>15.3</td>
<td>Data Confidentiality</td>
<td>31</td>
</tr>
<tr>
<td>15.4</td>
<td>Study Discontinuation</td>
<td>31</td>
</tr>
<tr>
<td>16</td>
<td>Data Handling and Record Keeping</td>
<td>32</td>
</tr>
<tr>
<td>16.1</td>
<td>Data Management Responsibilities</td>
<td>32</td>
</tr>
<tr>
<td>16.2</td>
<td>Data Capture Methods</td>
<td>32</td>
</tr>
<tr>
<td>16.3</td>
<td>Study Data Retention</td>
<td>34</td>
</tr>
<tr>
<td>16.4</td>
<td>Protocol Deviations</td>
<td>34</td>
</tr>
<tr>
<td>17</td>
<td>Publication Policy</td>
<td>35</td>
</tr>
<tr>
<td>18</td>
<td>References</td>
<td>36</td>
</tr>
</tbody>
</table>
# LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB</td>
<td>antibiotic</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>AS</td>
<td>antibiotic stewardship</td>
</tr>
<tr>
<td>CAP</td>
<td>community-acquired pneumonia</td>
</tr>
<tr>
<td>DASON</td>
<td>Duke Antimicrobial Stewardship Outreach Network</td>
</tr>
<tr>
<td>DCRI</td>
<td>Duke Clinical Research Institute</td>
</tr>
<tr>
<td>DICON</td>
<td>Duke Infection Control Outreach Network</td>
</tr>
<tr>
<td>DOCR</td>
<td>Duke Office of Clinical Research</td>
</tr>
<tr>
<td>DOT</td>
<td>days of therapy</td>
</tr>
<tr>
<td>EHR</td>
<td>electronic health record</td>
</tr>
<tr>
<td>HCAP</td>
<td>healthcare-associated pneumonia</td>
</tr>
<tr>
<td>IDSA</td>
<td>Infectious Diseases Society of America</td>
</tr>
<tr>
<td>IRB</td>
<td>institutional review board</td>
</tr>
<tr>
<td>MRN</td>
<td>medical record number</td>
</tr>
<tr>
<td>PAR</td>
<td>post-antibiotic prescription review</td>
</tr>
<tr>
<td>PI</td>
<td>principal investigator</td>
</tr>
<tr>
<td>TMP-SMX</td>
<td>trimethoprim-sulfamethoxazole</td>
</tr>
<tr>
<td>UTI</td>
<td>urinary tract infection</td>
</tr>
</tbody>
</table>
# PROTOCOL SYNOPSIS

<table>
<thead>
<tr>
<th>Protocol Title:</th>
<th>A Multicenter, Three-Stage Cluster-Randomized Historically Controlled Crossover Trial to Determine the Feasibility and Outcomes from Two Antimicrobial Stewardship Interventions in Community Hospitals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase:</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Products:</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Objectives:</td>
<td>To evaluate the feasibility of implementing antimicrobial restriction and preauthorization vs. prospective audit and feedback in resource-limited community hospitals</td>
</tr>
<tr>
<td>Study Design:</td>
<td>Three-stage cluster-randomized historically controlled crossover trial</td>
</tr>
<tr>
<td>Study Population:</td>
<td>Patients who receive targeted or alternative antimicrobials, hospitalized in one of the four community hospitals</td>
</tr>
<tr>
<td>Number of Participants:</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Number of Sites:</td>
<td>4</td>
</tr>
<tr>
<td>Duration of Participant Participation:</td>
<td>Participation is at the hospital level. All hospitals will participate for 13 months.</td>
</tr>
<tr>
<td>Dose Schedule:</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Estimated Start:</td>
<td>August 1\textsuperscript{st} 2014</td>
</tr>
<tr>
<td>Estimated Time to Complete Enrollment:</td>
<td>13 months for study duration</td>
</tr>
</tbody>
</table>
STUDY DESIGN SCHEMA

Stage 1

- One year retrospective data from hospitals
- Hospitals randomized
- Two hospitals implement stewardship strategy one
- Two hospitals implement stewardship strategy two

Stage 2

- One month washout period

Stage 3

- Stage 2 Strategy one hospitals implement stewardship strategy two
- Stage 2 Strategy two hospitals implement stewardship strategy one
1 KEY ROLES

For questions regarding this protocol, contact:

A) Study Principal Investigator:

Deverick Anderson, MD, MPH
Professor of Medicine – Infectious Diseases
Duke University Medical Center
Duke Box 102359
Hanes House, Room 165
Durham, NC 27710
Telephone: 919-684-4596
Fax: 919-681-7494
E-mail: deverick.anderson@duke.edu
2 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE

2.1 Background Information
Hospitals in the United States have observed increasing rates of drug-resistant pathogens and healthcare facility associated \textit{Clostridium difficile} infection, leading to significant burdens of morbidity, mortality, and hospital costs.\textsuperscript{1-3} A causal relationship between antibiotic exposure and acquired drug resistance is well established. However, 30\% to 50\% of antibiotic use in US hospitals is inappropriate.\textsuperscript{1,4} Hospital-level quality improvement programs to improve antibiotic stewardship (AS) are an essential intervention to curb these concerning trends.\textsuperscript{5}

2.2 Scientific Rationale
The Infectious Diseases Society of America (IDSA) guidelines recommend two “core” strategies for AS: 1) antimicrobial restriction and preauthorization and 2) prospective audit with intervention and feedback.\textsuperscript{1} Community hospitals have limited or no resources and staff dedicated to AS.\textsuperscript{6} Thus, understanding which of the core strategies is most effective in this practice setting would assist in appropriate allocation of limited resources.

2.3 Potential Risks and Benefits

2.3.1 Potential Risks
Potential risks are minimal due to the fact that all patients will continue to receive treatment per usual care. This study will provide an extra level of examination into the appropriateness of the prescribed antibiotic through AS interaction of prescribing physicians with trained pharmacists.

2.3.2 Benefits
Patients may benefit from having more attention paid to the course of treatment for their infections. Patients may receive more appropriate antimicrobial treatment, including using appropriate antimicrobial agents when an infection is present and stopping antimicrobial agents when they are unnecessary.
3 OBJECTIVES

The purpose of this study is to evaluate the feasibility of implementing antimicrobial restriction and preauthorization vs. post antibiotic prescription review in resource-limited community hospitals.

3.1 Study Hypotheses and Objectives

3.1.1 Hypotheses

- Primary Feasibility Hypothesis

The protocol of two stewardship strategies [Antimicrobial restriction and preauthorization and post-antibiotic prescription review] will receive approval at hospitals. The two stewardship strategies will both be successfully implemented, including training of local pharmacists (PharmDs), at all four hospitals.

Secondary Stewardship Hypotheses

1. Antimicrobial restriction and preauthorization will be less resource-intensive for hospitals (e.g., set-up time, approval time, personnel resources) than post-antibiotic prescription review (PAR) and feedback.

2. Prescribers will consider preauthorization to be intrusive to clinician autonomy and patient care.

3. The cost of performing PAR by a trained pharmacist will be offset by the cost savings achieved by decreasing antimicrobial cost.

4. Both strategies will lead to a decrease in utilization for targeted antimicrobials relative to utilization in the period prior to implementation of the stewardship strategies.

5. Decreases in targeted antimicrobial utilization from antimicrobial restriction will be offset by increases in use of alternative antibiotics.

6. The strategy of antimicrobial restriction and preauthorization will be less effective at reducing overall antimicrobial use than the strategy of prospective audit and feedback, as it will not shorten duration of antimicrobial therapy.

3.1.2 Primary Objectives

Feasibility Objectives

1. To evaluate having the protocol of two stewardship intervention strategies approved by hospital administration and committees

2. To evaluate the training of local PharmDs in administration of the two stewardship strategies

3. To evaluate the initiation and implementation of the two stewardship strategies at four hospitals
3.1.3 Secondary Objectives

To estimate and compare the time required of the pharmacist to administer each strategy

1. To estimate and compare the resource utilization of each strategy, where resource utilization includes pharmacist time and cost of antibiotics.

2. To compare the days of therapy (DOT) for antibiotics of interest between each strategy
   DOT will be measured as the number of days a patient receives each targeted and alternative antibiotic during the hospital admission.

3. To compare patient-specific outcomes between each strategy, including but not limited to the following:
   a. Total hospital days
   b. Death
   c. Intensive care unit admission

4. To compare the prescriber and pharmacist perceptions of the two stewardship strategies

5. To develop integrated measures of benefit: risk for AS (based on days of therapy, hospital days, and patient outcomes such as ICU admission and survival) and compare strategy effects with respect to these measures

3.1.4 Exploratory Objective

To evaluate the interpretations reached from analysis of data based on traditional (DOT/patient-days) outcomes as compared to newer proposed outcomes (defined in Section 3.1.3 Secondary Objectives, number 5).
4 STUDY DESIGN

This study is a three-stage cluster randomized historically controlled crossover trial designed to evaluate the feasibility of the implementation of two AS strategies. Data will be obtained from four community hospitals in three stages. In stage 1, historical data from each hospital will be collected for the year prior to study initiation from all participating hospitals. These data are used as a control representing current practice. In stage 2, the four hospitals will be divided into two pairs based upon bed size. One hospital from each pair will be randomly assigned to a six-month period of antimicrobial restriction and preauthorization (Strategy 1; stage 2) followed by a six-month period of post-antibiotic prescription review (Strategy 2; stage 3). The other two hospitals will undergo Strategy 2 in stage 2 followed by Strategy 1 in stage 3 to help alleviate the concern for seasonal/temporal effects when comparing the strategies to each other. Temporal/seasonal effects are not controlled when comparing to the historical control. A one-month wash out will be performed between each stage. Three antibiotics will be specifically targeted for intervention: anti-pseudomonal carbapenem of choice at the study hospital, vancomycin, and piperacillin-tazobactam. Utilization of alternative antimicrobials, including fluoroquinolones, cephalosporins, and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) systemic antimicrobials (e.g., nafcillin, daptomycin, linezolid, ceftaroline, clindamycin, and trimethoprim-sulfamethoxazole [TMP-SMX]) will also be collected.

4.1 Study Population

4.1.1 Selection of the Study Population

Four community hospitals in the Duke Infection Control Outreach Network (DICON) will be recruited for this study. Ideally, hospitals will have no teaching affiliation, bed size <300, and no existing antimicrobial formulary restriction and preauthorization or PAR practices in place at study start.

Drug use Identification: All study hospitals will have electronic systems that track antimicrobial prescriptions through orders, electronic medication administration records (eMAR), bar-coded medication administration (BCMA), or dispensing data.

4.1.2 Inclusion/Exclusion Criteria

Inclusion criteria: All adult and pediatric patients admitted to the study hospital who are prescribed targeted or alternative antimicrobial agent(s) will have data collected from their medical records.

Exclusion criteria: Any patient not meeting the criteria above will be excluded. Patients who receive < 24 hours of surgical prophylaxis with a targeted or alternative antimicrobial will be excluded.
4.1.3 Treatment Assignment Procedures

The four hospitals will be divided into two pairs based upon bed size and in discussion with the protocol team. One hospital in each pair will implement Stewardship strategy 1 followed by Stewardship strategy 2. The other hospital in each pair will implement Stewardship strategy 2 followed by Stewardship strategy 1. The order of the strategies will be randomly generated at the SDMC and communicated to the local PharmD and pre-identified hospital staff.

4.1.4 Stewardship Strategy Descriptions

Hospitals will have dedicated clinical pharmacist time for preauthorization or post-antibiotic review for the three targeted antibiotics in each arm of the study. One PharmD at each site will receive standardized training by study personnel in order to address common questions and anticipated arguments, and to establish a robust knowledge base regarding the targeted antimicrobials (anti-pseudomonal carbapenem of choice at the study hospital, vancomycin, and piperacillin-tazobactam). They will also be trained in conflict management.

Study personnel will provide suggested criteria for appropriate use of each targeted drug. Hospital P&T committees will review, edit (if desired), and approve hospital-specific protocols for appropriate use criteria for each study drug. On-site pharmacists will then use the local criteria to determine whether each prescription falls into protocol vs. non-protocol use and then recommend approval/disapproval and/or alternative therapy to the prescriber in real time.

Each participating pharmacist will be thoroughly trained by study staff prior to the study. Pharmacists will be provided with specific clinical pathways for urinary tract infections (UTIs), community-acquired pneumonia (CAP), healthcare-associated pneumonia (HCAP), bacteremia, and “other” uses of targeted antimicrobial. Clinical pathways will be developed jointly by study personnel and based on Centers for Disease Control and Prevention pilot projects. Clinical pharmacists will determine appropriateness of therapy based on study clinical pathways, their baseline knowledge, and acquired knowledge derived by training from study personnel. Time spent performing the two stewardship strategies will be supported by grant funds. The designated pharmacist will be involved in two critical components of the protocol: a) completing the intervention and b) documenting the outcome of the intervention.

Stewardship Strategy 1 – Antimicrobial restriction and Pre-authorization. Following approval of the protocol at study hospitals, all prescriptions for targeted antibiotics will require phone approval by the trained PharmD. Prescribers will be instructed to discuss the patient details and the rationale for the desired antimicrobial with the PharmD. Specifically, prescribers must contact the pharmacist via pager or phone call to discuss the rationale for using the targeted antibiotic. The pharmacist will discuss the rationale and the specific clinical scenario with the prescriber and will decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will then document this interaction in the REDCap database, documenting which targeted antibiotic was requested, the prescriber’s rationale for requesting the targeted antibiotic, the patient’s symptoms and pertinent
clinical data at the time of the request, whether the request met the criteria for use of the targeted antibiotic (or not), and the pharmacist’s recommendation. Prescriptions for targeted antibiotics will be eligible for intervention if written between 7am and 6pm Monday through Friday. Off-hours prescriptions will be reviewed for approval for continuation the following morning.

Stewardship Strategy 2 – Post-antibiotic Review and Feedback. Following approval of the protocol at study hospitals, all prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The clinical pharmacists will review a list of patients receiving the targeted antibiotics on a daily basis to identify patients who have received one or more targeted antibiotics for 72 hours (± 24 hours). The pharmacist will review and document the patient’s current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber (i.e., by pager, by phone call, or during clinical rounds) to discuss the pharmacist’s recommendations. The interaction will be documented in the REDCap database, including whether or not the prescriber is going to follow the pharmacist’s advice. If the pharmacist concludes that the antibiotic is appropriate, then he or she will document that the antibiotic is appropriate but will not be required to contact the prescriber.

Follow up: Strategy 1 and Strategy 2 -- For both strategies, the pharmacist will review the patient’s chart approximately five days after interacting with the prescriber to document whether the pharmacist’s recommendation was followed. The pharmacist will specifically document if the recommendation was followed, the recommended duration of antibiotic, whether the dose of the antibiotic was appropriate, and the ultimate infection diagnosis. If the patient has already been discharged, the pharmacist will review the patient record to gather this information.

4.1.5 Termination of Study

This study may be terminated at any time by the principal investigator (PI) in consultation with the Antibacterial Resistance Leadership Group (ARLG).
5 STUDY PROCEDURES

5.1 Data Collection

- Data will be collected on the following topics:
  - Feasibility
  - Strategies
  - PharmD chart and prescription review
  - PharmD/Prescriber communication
  - PharmD follow-up
  - Pharmacist time
  - Pharmacist and Prescriber perceptions (questionnaires)
  - Secondary/Exploratory Objectives: DASON database (Pharmacy data, Admit/Discharge Table, Billing ICD9, Microbiology Lab, Bed Flow)

- The PharmD will provide patient data from two time points: first contact and at the time of discharge. In strategy 1, first contact will be the PharmD/prescriber contact and discussion. In strategy 2, first contact will be the date of the PharmD review (approximately 72 hours after the targeted antibiotic was started).

Endpoints

Primary endpoints (measured at the hospital level):

- Approval of interventions by hospital administration and committees
- Successful completion of training of a local PharmD
- Initiation of the intervention protocols

Secondary endpoints (measured at the patient level):

- DOT for each of the targeted and alternative antibiotics
- Duration of hospitalization
- Admission to the ICU (yes/no)
- Duration in ICU
- Discharged vs. death
- Benefit: risk measures to be developed as composites of other outcomes (details provided in an analysis plan)

Exploratory endpoints (measured at the patient level):

Comparison of utilization outcomes

Data Monitoring
No formal interim analyses involving hypothesis testing are planned. Data from the retrospective portion of the study will be cleaned and transmitted upon completion to conduct further cleaning and prepare for analyses.

Pharmacists will be provided with a data entry guideline (DEG) to ensure consistent data collection across participating hospitals.

5.2 Other Study Procedures

We will not enroll subjects as part of this protocol. Therefore, the following sections are not applicable:

Screening

1. Enrollment/baseline
2. Follow-up
3. Final study visit
4. Follow-up safety phone call
5. Early termination visit
6. Unscheduled visit
7. Laboratory evaluations
6 STUDY PRODUCT DESCRIPTION

Not applicable

6.1 Concomitant Medications/Treatments

Not applicable
7 ASSESSMENT OF SAFETY

We are not enrolling patients; therefore, the following sections are not applicable:

1. Specifications of safety parameters
2. Methods and timing for assessing, recording, and analyzing safety parameters
3. Guidelines for assessing intensity of an adverse event (AE)
4. Guidelines for determining causality
5. Discontinuation due to AEs
6. Reporting procedures (for AE)
7. Type and duration of follow-up of participants after AEs
8. Halting rules
9. Safety oversight
8 CLINICAL MONITORING

ICH E6 states that the purpose of monitoring is to ensure the rights of subjects, obtain accurate data, and conduct the trial in accordance with protocol and applicable regulations. For the purposes of this protocol, a monitoring plan will be developed to ensure that three areas are adequately addressed.

Key areas that will be outlined will be the qualification of hospital personnel to conduct the trial, regulatory requirements (e.g. institutional review board [IRB] review), protocol training, data quality monitoring procedures, hospital data completion expectations (e.g. completeness, frequency), and pathways for issue escalation as well as for resolving any general questions at the hospitals.
9 STATISTICAL CONSIDERATIONS

9.1 Design and Sample Size Considerations

This is a feasibility study to evaluate if four hospitals can implement two antimicrobial stewardship interventions. Analysis of the primary feasibility components will be descriptive (a summary as to whether each hospital was able to successfully implement each of the interventions). No hypothesis testing will be completed for these summaries.

The secondary stewardship analyses may include hypothesis testing and estimation of the difference to the control as well as between the two stewardship strategies.

This study will collect data on all patients prescribed a targeted or alternative antibiotic at each of four hospitals, except patients who receive < 24 hours of surgical prophylaxis. The three targeted antibiotics are:

- Anti-pseudomonal carbapenem of choice at the study hospital
- Vancomycin
- Piperacillin-tazobactam.

The alternative antimicrobials of interest are:

- Fluoroquinolones
- Cephalosporins
- anti-MRSA systemic antimicrobials (e.g., nafcillin, daptomycin, linezolid, ceftaroline, clindamycin, and TMP-SMX).

This study will not target a specific number of patients to enroll. Instead, it will be conducted for specific periods of time. Each hospital will implement its first strategy for six months, followed by an one-month period with no strategy, and then a second, six-month period for the second strategy, for a total duration of 13 months. Additionally, one year of historical data from the four hospitals will be analyzed.

Although this study does not target a specific number of participants, hospitals are expected to admit at least 600 patients per month. Thus, we expect to have at least 3600 patients included in analyses for each six-month intervention period. When conducting within-hospital analyses, a conservative sample size of 3000 patients during each intervention period will achieve 97% power to detect a difference between the group proportions (e.g., of patients with no [0] DOT) of 0.0500 when the proportion in one group is 0.50 using an alpha of 0.05. The power for detecting a difference as a function of sample size is illustrated in Figure 9-1:
9.2 Planned Interim Analyses

As this is a strategy study that enrolls hospitals, there will be no planned interim analyses for safety in this protocol. We expect to summarize historical data while the prospective portion of the study is ongoing.

9.3 Participant Enrollment and Follow-Up

Data from participants admitted to the four hospitals during each of the two six month strategy periods are entered into the database. The data from admission until death or discharge are collected.
9.4 Analysis Plan

9.4.1 Analysis

9.4.1.1 Primary feasibility summaries
The primary analyses will be descriptive (a summary as to whether each hospital was able to successfully implement each of the interventions). No hypothesis testing will be completed for these analyses.

9.4.1.2 Secondary analyses
The analyses of the secondary objectives will consist of multiple analyses to address the hypotheses. The endpoints required for these analyses include, but are not limited to:

- Days of targeted and alternative antimicrobial use
- Prescriptions for targeted and alternative antimicrobials
- Days in hospital
- Death
- ICU admission
- Survey of provider perceptions
- Costs including cost of pharmacist and antimicrobial costs

9.4.1.3 Discussion of cluster randomized design and the key secondary analysis
This antimicrobial stewardship study will be implemented at four hospitals, where each hospital is considered a single cluster. The four hospitals participating in this study will be paired by size. One hospital in each pair will receive Strategy 1 followed by Strategy 2, while the other hospital in each pair will receive Strategy 2 followed by Strategy 1. The ordering within each pair will be randomly assigned.

Cluster randomized trials can be analyzed at the cluster level or the patient level. Ideally, analyses are conducted on the cluster level as this is the unit of randomization. However, we will analyze this study using the patient as the unit of analyses as there are only four clusters.

Since randomization occurs at the cluster level but analyses must be conducted at the patient level, the benefits of randomization (i.e., expectation of balance of confounding factors) cannot be assumed. The small sample size of 4 clusters may also negate the benefits of randomization. The crossover nature of the design will help to balance confounding factors as each hospital can serve as its own control. However, as the crossover occurs at the cluster level, and the patients are neither randomized nor crossed-over, it does not have the same advantages as a standard crossover trial and it does not eliminate within-patient variation; the analyses cannot be “paired”.
Since the effect of the intervention is not only a function of the intervention itself but also of the pharmacist, there is potential for considerable site variation in response. Thus each of the four sites will be evaluated separately. Stratified pooled analyses may also be conducted.

For each site and each contrast (Intervention 1 vs. control; Intervention 2 vs. control; and Intervention 1 vs. Intervention 2), the difference in outcomes will be estimated using 95% confidence intervals. Examples for binary and continuous outcomes are displayed in Figure 9-2 and Figure 9-3, respectively.

Figure 9-2

95% CI for Difference in Proportions (Intervention 1 – Intervention 2)
Summarized Overall and by Site

OUTCOME

- Death
- ICU Admission
- DOT=0
- Hospital
- Days > X
- Readmission
Site heterogeneity of treatment effects will be explored by modeling outcome as a function of treatment, period, site, and period*site interaction. Age, sex, and race will also be included to control for confounding by demographic variables. Treatment and period effects will be fixed. Site and period*site effects will be random.

Exploratory analyses of the overall benefits and risks of the AS interventions will also be conducted using methods that are currently being developed.

### 9.4.2 Data Acquisition

Cost and feasibility data will be obtained using hospital cost data (antibiotics and pharmacy FTE), questionnaires, and notes/observations created during interactions with hospital personnel. Patient endpoint data will be obtained from electronic pharmacy antibiotic prescribing data (start and stop dates for all antibiotics) and hospital databases (e.g., ADT data for admit/discharge dates for all patients; patient status database (mortality); and diagnosis code databases).
9.4.3 Limitations and Potential Solutions.

The above study approach has limitations. First, the study is essentially non-randomized. Even randomization of hospitals cannot guarantee the balance of confounding factors on the unit of analyses (patients). The cross-over design helps to alleviate this concern as each hospital would be expected to enroll similar populations into each intervention period.

Second, our designed strategies may miss intervention opportunities. Our study design includes pharmacist interventions during business hours on Monday through Friday and does not include weekend interventions. This inclusion criterion will impact Strategy 1 more than Strategy 2, as no alternative approach is available for Strategy 1. To overcome this limitation for Strategy 2, we will allow the intervention to occur within 72 hours of prescription ± 24 hours, if necessary. This window for intervention will be adequate to intervene on all antibiotic prescriptions. We believe that this approach is appropriate, as we suspect this approach is likely to mirror how most hospitals will eventually implement each of these interventions; thus, it is more likely to lead to true conclusions regarding the feasibility and outcomes of each of these interventions.

Third, the short study period and limited study sites will hinder our ability to demonstrate definitive changes in our secondary analyses, including changes in antimicrobial utilization. The primary goal of this study, however, is to assess feasibility.

Next, the effectiveness of any stewardship program is likely to vary depending on the experience and expertise of the pharmacist performing the PAR and local hospital culture. In fact, we will specifically measure pharmacist variables (e.g., years of experience, experience with stewardship, and training in infectious diseases) to identify barriers to successful implementation of PAR. We will, however, perform pre-intervention standardized training for all pharmacists by a highly experienced and seasoned pharmacist educator in order to make sure all participating pharmacists have appropriate competency.

Given that the strategies are applied at the hospital level, there is the potential for selective entry, i.e., patients and others may be aware of the stewardship strategy prior to enrolling into the study.

Finally, as the primary control group is historical, subsequent comparisons may be biased by temporal effects. The crossover nature of the trial design helps to alleviate this bias inherent to comparing the AS interventions in pooled analyses.
10 STUDY IMPLICATIONS

Results from this study will provide valuable information for planning a large, multicenter study investigating one or both of the proposed interventions in community hospitals. For example, subsequent research could be limited to one intervention, depending on the feasibility determined in this pilot study. In addition, important parameters will be available to inform power calculations for future cluster-randomized trials.
11 PARTICIPANT CONFIDENTIALITY

Appropriate waivers of consent and HIPAA authorization will be obtained at all sites.
12 INFORMED CONSENT PROCESS

Appropriate waivers of consent and HIPAA authorization will be obtained from all local IRBs overseeing hospitals.
13 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS

No source documents will be used by this protocol.
14 QUALITY CONTROL AND QUALITY ASSURANCE

The PI will ensure that all study personnel are appropriately trained and applicable documentations are maintained.

The DCRI will implement a Quality Plan to, at a minimum, ensure that activities proposed by the PI to ensure protocol training, data quality and data security are being undertaken.
15 ETHICS/PROTECTION OF HUMAN PARTICIPANTS

15.1 Institutional Review Board
The investigator will ensure that the protocol is reviewed and approved by the appropriate IRB prior to the start of any study activities. The IRB will be appropriately constituted and will perform its functions in accordance with US regulations, ICH Good Clinical Practice guidelines, and local requirements as applicable.

15.2 Informed Consent
This study does not involve the enrollment of participants; appropriate waivers of consent and HIPAA authorization will be obtained from all local IRBs overseeing hospitals.

15.3 Data Confidentiality
The study protocol, documentation, data, and all other information generated by this study will be maintained in a secure manner and will be kept confidential as required by law. In order to meet federal or state regulations, this information may be reviewed by the FDA, IRBs, the sponsor and its representatives, or the NIH.

Data access will be limited to study personnel, and the data will be stored on servers with limited physical access (e.g., locked rooms) and limited electronic access (e.g., password-controlled access to data, computers, and, if applicable, networks). No information concerning the study or the data will be released to any third party without prior written approval of the ARLG.

15.4 Study Discontinuation
This study may be terminated at any time by the PI in consultation with the ARLG.
16 DATA HANDLING AND RECORD KEEPING

16.1 Data Management Responsibilities

The hospitals will enter data into the ARLG DICON1 database via Research Electronic Data Capture (REDCap; see Data Capture Methods below). Other data will come from the ARLG DICON1 EHR database. DICON Network personnel will reconcile the data, strip out the MRN identifiers, and provide DCRI with an ARLG DICON1 limited database with the DICON ID as the subject identifier. These limited datasets will be sent to DCRI as the data coordinating center. DCRI will send the data to the Harvard Statistical Center for analysis.

16.2 Data Capture Methods

REDCap is a toolset and workflow methodology for electronic collection and management of research and clinical trial data. Both REDCap and REDCap Survey systems provide secure, web-based applications that are flexible enough to be used for a variety of types of research, provide an intuitive interface for users to enter data and have real time validation rules (with automated data type and range checks) at the time of entry. These systems offer easy data manipulation with audit trails and reporting for reporting, monitoring and querying patient records, and an automated export mechanism to common statistical packages (SPSS, SAS, Stata, R/S-Plus).

The REDCap program will serve as the portal for data entry at remote study hospital locations. Data entered into this database will be password protected and only accessible by study personnel. All access to this secure separate database will be monitored and logged.

This REDCap database will be created and managed by the DCRI and hosted by DOCR at Duke. MRN will be stripped from REDCap data sent to DCRI.

EHR data from the hospitals are sent to Duke DASON from each of the study hospitals through routine DASON activities. These data files are sent via secure File Transfer Protocol (sFTP) to servers and are available on shared drives kept behind DUHS firewalls. By standard DASON procedure, these data are typically stripped of PHI except dates prior to transmission to DUHS. Individual patients are instead identified by a “DICON ID”. For the purposes of this study, however, we will eliminate the step that removes PHI so that MRN is provided in these files. This specific data variable is required to connect the data received from the pharmacist intervention database to the EHR database. The MRN will be stripped out of the datasets sent to DCRI.

Specific Data Management. Given the number of hospitals involved in the study and the various types and sources of data to be used, consideration must be given to each type and location of data required for the study.
1. **Pharmacist intervention forms** - These REDCap forms will be created and managed by DCRI and hosted by DOCR at Duke. The pharmacist at each site will complete these forms for each intervention. These data will include PHI such as MRN. Data from these forms represents the only subject level data specifically generated for this study. MRN data will not be included in the transfers to DCRI.

2. **Pharmacist time forms** - These REDCap forms will be completed by the pharmacist at each hospital and will provide information concerning the time spent on the interventions.

3. **Hospital level forms** - These REDCap forms will be completed by DASON personnel. These data will include information regarding the approval and implementation of the stewardship strategies at each hospital.

4. **Questionnaires** - These REDCap questionnaires will be completed by the pharmacists and prescribers at each hospital after each strategy is completed (at the end of the six month period). Pharmacists and prescribers will be sent a link to the questionnaires in order to complete. These will not require a REDCap account.

5. **Pharmacy data** - Antimicrobial utilization data are sent to Duke DASON from each of the study hospitals through routine DASON activities. These data will include PHI such as MRN and dates. These data are created through routine hospital pharmacy activities. These data files will include PHI such as MRN and dates. These data will be transmitted to DUHS via the same sFTP established for routine transmission of data described above. MRN data will not be included in the transfers to DCRI.

6. **Bed Flow and Admission-Discharge-Transfer (ADT) data** – We will receive bed flow (patient movement within the hospital) and ADT files from study hospitals on a monthly basis through standard DASON activities. These data files will include PHI such as MRN and dates. These data will be transmitted to DUHS via the same sFTP established for routine transmission of data described above. MRN data will not be included in the transfers to DCRI.

7. **Demographics data** - We will receive data from study hospitals on a monthly basis through standard DASON activities. These data files will include PHI such as MRN and dates. These data will be transmitted to DUHS via the same sFTP established for routine transmission of data described above. MRN data will not be included in the transfers to DCRI.

8. **Billing/ICD-9 data** - We will receive data from study hospitals on a monthly basis through standard DASON activities. These data files will include PHI such as MRN and dates. These data will be transmitted to DUHS via the same sFTP established for routine transmission of data described above. MRN data will not be included in the transfers to DCRI.

9. **Microbiology data** - We will receive data from study hospitals on a monthly basis through standard DASON activities. These data files will include PHI such as MRN and dates. These data will be transmitted to DUHS via the same sFTP established...
for routine transmission of data described above. MRN data will not be included in the transfers to DCRI.

16.3 Study Data Retention

Research records and data must be kept for a minimum of 6 years after final reporting or publication.

16.4 Protocol Deviations

Not applicable.
17 PUBLICATION POLICY

Following completion of the study, the investigator may publish the results of this research in a scientific journal under the oversight of the Publication Committee of the ARLG.
18 REFERENCES


5. Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2012;33:322-7.
